Current Research Studies

Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < 18 years of age

Rimegepant 312

What is the goal of the study?

To evaluate the safety and tolerability of rimegepant in children and adolescents (age ≥ 6 to < 18 years of age).

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: